Nuvation Bio Inc. Class A Common Stock vs Ross Stores, Inc. — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Ross Stores, Inc. trades at $226 (market cap $72.05B). The key difference: Ross Stores, Inc. is far larger — about 42.1× Nuvation Bio Inc. Class A Common Stock's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Ross Stores, Inc. for 48 Days on average.
| NUVB | ROST | |
|---|---|---|
Market Cap | $1.71B | $72.05B |
Volume | 5,448,712 | 1,674,861 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.54 | $255.23 |
52-Week Low | $3.41 | $147.71 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $1.30B | $72.50B |
Dividend Yield | — | 0.79% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ross Stores (ROST) trades at $225.20, up 0.44% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics including 42.63% ROE and 10.85% net margin. The stock faces technical headwinds with a bearish signal from moving averages, trading near support at $224. Recent news highlights store expansion initiatives and strong closeout supply benefits as the company captures value-conscious shoppers amid competitive retail pressures.
ROST presents a compelling investment case with analyst consensus pointing to 22% upside to the $274.14 price target, supported by strong earnings momentum and expanding margins. Key risks include retail competition, cost pressures, and macroeconomic sensitivity, but the company's value-focused strategy and operational discipline position it well for sustained growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →